Contribute
España
Italia
대한민국
日本
Français

Benzinga

Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
767.510.06%
QQQ
716.700.01%
BTC/USD
78339.860.2818%
DIA
532.040.09%
GLD
408.230.05%
TLT
82.380.17%

Boundless Bio Inc

BOLDNASDAQ
Trade with Public
Trade with Public
$2.81
-0.02-0.71%
At close: Aug 31, 5:00 PM EST
$2.82
0.00540.19%
After Hours: 5:36 PM EST
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipCompareStock Report

Boundless Bio Analyst Price Targets

Wall Street analyst price targets and consensus rating for Boundless Bio (BOLD).

Price Target Range — 3 Quarters

Analyst Consensus — 4 Analysts

2Buy
2Hold
Consensus RatingBuy# Analysts4Avg. Consensus PT$8Upside to Avg. PT+184.2%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 11, 2025HC Wainwright & Co.Mitchell S. KapoorPT CutBuy$5→$4
Jun 2, 2025HC Wainwright & Co.Mitchell KapoorInitiateBuy$5
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
HC Wainwright & Co. Maintains Buy on Boundless Bio, Lowers Price Target to $4

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Boundless Bio (NASDAQ:BOLD) with a Buy and lowers the price target from $5 to $4.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Initiates Coverage On Boundless Bio with Buy Rating, Announces Price Target of $5

HC Wainwright & Co. analyst Mitchell Kapoor initiates coverage on Boundless Bio (NASDAQ:BOLD) with a Buy rating and announces Price Target of $5.
Benzinga Newsdesk

PRO
Leerink Partners Downgrades Boundless Bio to Market Perform, Lowers Price Target to $3

Leerink Partners analyst Michael Cherny downgrades Boundless Bio (NASDAQ:BOLD) from Outperform to Market Perform and lowers the price target from $15 to $3.
Benzinga Newsdesk

PRO
Guggenheim Downgrades Boundless Bio to Neutral

Guggenheim analyst Yige Guo downgrades Boundless Bio (NASDAQ:BOLD) from Buy to Neutral.
Benzinga Newsdesk

PRO
Leerink Partners Initiates Coverage On Boundless Bio with Outperform Rating, Announces Price Target of $25

Leerink Partners analyst Michael Cherny initiates coverage on Boundless Bio (NASDAQ:BOLD) with a Outperform rating and announces Price Target of $25.
Benzinga Newsdesk

PRO
Guggenheim Initiates Coverage On Boundless Bio with Buy Rating, Announces Price Target of $24

Guggenheim analyst Yige Guo initiates coverage on Boundless Bio (NASDAQ:BOLD) with a Buy rating and announces Price Target of $24.
Benzinga Newsdesk

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved